Drug, bio-affecting and body treating compositions inventions 07/07

20070172424 - Enabling drug adherence through closed loop monitoring & communication: A method is described for measuring the blood concentration of a medicament through the introduction of a tracer compound. The measurement of the blood concentration of the tracer will yield a result that will enable a prediction of the blood concentration of the medicament. The method further describes ways to... Agent: Janus Medical Instruments, Inc.

20070172432 - Biodegradable hemostatic compositions: Biodegradable hemostatic compositions are provided including nucleic acids. The nucleic acids may be obtained from plant sources, animal sources, or combinations thereof, or they may be synthetic. The hemostatic compositions of the present disclosure are non-inflammatory, and are degraded in an animal's body after successfully re-establishing hemostasis of a tissue... Agent: United States Surgical, A Division Of Tyco Healthcare Group Lp

20070172431 - Methods, systems and compositions for skin care: The present invention describes systems, methods, and compositions for treatment and maintenance of skin. The invention includes a skin care system that addresses the problems of skin aging and inflammation. The invention further includes skin care systems, methods and compositions containing active ingredients that may inhibit matrix metalloproteniases (MMPs) or... Agent: Troutman Sanders LLP

20070172422 - Exponential pattern recognition based cellular targeting compositions, methods and anticancer applications: The present invention relates to the compositions, methods, and applications of a new approach to pattern recognition based targeting by which an exponential amplification of effector response can be specifically obtained at a targeted cells. The purpose of this invention is to enable the selective delivery of large quantities of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070172420 - Ligands: and pharmaceutically-acceptable salts thereof, wherein R1 and Ar are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070172421 - Substituted pyrrolidine-2-ones: d

20070172423 - Composition and method for modulating vasculogenesis for angiogenesis: A method for modulating vasculogenesis or arteriogenesis or angiogenesis, especially for treating heart and limb ischemia, using the core domain protein of PDGF-C, a new member of the PDGF/VEGF family of growth factors, or a homodimer or a heterodimer comprising the core domain. Also disclosed are pharmaceutical compositions comprising the... Agent: Crowell & Moring LLP Intellectual Property Group

20070172425 - Testing cell cycle regulation effect of a compound using a hollow fibre cell implant: The invention includes an in vivo pharmacodynamic method for testing a compound for cell cycle regulation.... Agent: Astrazeneca R&d Boston

20070172426 - Polymer coated microparticles: Methods for preparing uniformly sized microparticles, with an optional polymeric coating generally include: 1) providing nanoparticles, preferably having a size of between 1 nm and 100 nm; 2) adding a hydrophobic surface layer to the nanoparticles; 3) making a suspension of the hydrophobic nanoparticles and a polymerization initiator in an... Agent: Woodard, Emhardt, Moriarty, Mcnett & Henry LLP

20070172427 - Biofunctionalized quantum dots for biological imaging: Novel biofunctionalized quantum dots include a mercaptoalkanoic acid linked to the surface of a nanocrystalline core and a bio-functional group linked to the surface. Biofunctionalized quantum dots are made by a novel synthesis method. Biofunctionalized quantum dots can be used in imaging or therapy applications.... Agent: Venable LLP

20070172428 - Multivalent constructs for therapeutic and diagnostic applications: The invention provides compositions and methods for therapeutic and diagnostic applications.... Agent: Kramer Levin Naftalis & Frankel LLP

20070172429 - Labeling compositions and methods of use for deterrent trackability: Compositions and methods for controlling and tracking items are provided. More particularly, labeling compositions useful as a coding system to deter diversion of items of medication or other valued items are provided, wherein the labeling compositions comprise at least 25 unique identifiers, wherein the at least 25 unique identifiers are... Agent: Sutherland Asbill & Brennan LLP

20070172430 - Dry powder compositions for rna influenza therapeutics: A dry powder formulation for mucosal, intranasal, inhalation or pulmonary delivery which may include one or more siRNAs or dicer-active precursors thereof targeted to a transcript involved in infection by, or replication or production of an influenza virus.... Agent: Nastech Pharmaceutical Company Inc

20070172434 - Antimicrobial dental materials, restorations, and prostheses: The present invention relates to compositions and methods for antimicrobial dental materials in the restoration of the sequelae of oral infections including replacement of oral tissues lost to disease and prevention of additional infections.... Agent: Merchant & Gould PC

20070172433 - Biometic compounds containing hydroxyapatites substituted with magnesium and carbonate, and the processes used to obtain them: Carbonate hydroxyapatites containing magnesium, composite materials consisting of said hydroxyapatites and natural polymers are described; processes for the preparation of said materials and their use in orthopaedics and dentistry fields are also described.... Agent: Jay S. Cinamon Abelman, Frayne And Schwab

20070172435 - Medicament for internal application, in particular against cancerous diseases: The invention relates to a medicament for internal application, in particular against cancerous diseases. The medicament comprises polydimethylsiloxane and surfactants, whereby the proportion of polydimethylsiloxane is greater than the proportion of surfactants.... Agent: Mccarter & English Basam E Nabulsi

20070172436 - Nonaqueous ascorbic acid compositions and methods for preparing same: A method for preparing a nonaqueous ascorbic acid composition in an alcohol solvent comprising ascorbic acid, a solubilization enhancer, and an oleaginous skin protectant is described. The amount of ascorbic acid dissolved in the nonaqueous composition in the presence of the solubilization enhancer is greater than the amount of ascorbic... Agent: Jerry Zhang

20070172437 - Solubilizing agents for active or functional organic compounds: An active or functional organic compound is solubilized by an ester of an aryl alcohol, e.g., phenethyl, benzyl or substituted benzyl alcohol, and an alkyl or cycloalkyl carboxylic acid, or by a carbonate of said aryl alcohol and an alkyl or cycloalkyl carbonic acid.... Agent: Attn: William J. Davis, Esq. International Specialty Products

20070172438 - Comestic preparation containing a metallic pigment: The invention relates to a cosmetic preparation containing a metallic effect pigment which consists of a metal substrate having a layer enclosing the substrate. Said layer is produced in a sol/gel method, has a barrier effect against sweat and saliva and prevents a direct contact between skin and metallic substrate,... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172439 - Method of chemiluminescence-utilizing makeup and beautification, luminant for skin irradiation beautification and makeup/beautification equipment: Presentation of the methods for makeup and beauty treatment by chemical luminescence, luminous bodies for beauty treatment by exposure to skin, and tools for makeup and beauty treatment... Agent: Knobbe Martens Olson & Bear LLP

20070172440 - Transparent cosmetic microemulsion-based formulation containing an alpha-hydroxy-carboxylic acid: The invention relates to a clear, microemulsion-based cosmetic formulation with reduced stickiness, comprising at least one antiperspirant active ingredient and/or deodorant active ingredient and α-hydroxycarboxylic acid.... Agent: Greenblum & Bernstein, P.L.C

20070172441 - Cation-modified purified galactomannan polysaccharide and cosmetic composition containing the substance: (where R1 and R2 each independently represent an alkyl group having 1 to 3 carbon atoms; R3 represents an alkyl group having 1 to 24 carbon atoms; X− represents an anion; n is either 0 or 1 to 30; and, when n is 1 to 30, (R4O)n represents a polymer... Agent: Oliff & Berridge, PLC

20070172442 - Topical compositions associating sodium hyaluronate fragments and retinoid useful for cosmetic and medical dermatology: The inventive compositions for topical application are characterised in that they comprises one or several hyaluronate fragments in the form of a main principle whose molecular weight ranges from 50 000 and 750 000 Da and a retinoid if necessary.... Agent: Birch Stewart Kolasch & Birch

20070172443 - Anti-chlorine shampoo composition: Retention of chlorine and hypochlorite in hair is reduced by treating the hair with a defined composition, allowing the composition to remain on the hair for at least 10 seconds, and then rinsing off the composition with water. The composition comprises at least 1% by total weight of the composition... Agent: Mark A. Litman & Associates, P.A. York Business Center

20070172444 - Hair tonics and method of screening the same: There is provided a hair tonic comprising at least two of an inhibitor against 5α reductase type 2, an inhibitor against transforming growth factor β2, and an inhibitor against caspase-3; a method comprising screening for at least two of inhibition against 5α reductase type 2, inhibition against transforming growth factor... Agent: Snider & Associates

20070172445 - Chronic articular inflammation-modulating composition based on collagen-polyvinylpyrrolidone: The invention relates to a chronic articular inflammation-modulating composition which uses collagen-polyvinylpyrrolidone. Collagen turnover is modulated using collagen-PVP in patients with rheumatoid arthritis and osteoarthritis, since the biocomplex negatively regulates collagenolytic activity and increases the content of type III collagen and TIMP-1 to levels similar to those observed in normal... Agent: Jones Day

20070172448 - method for detecting the specificity of activated lymphocyte: A method for detecting the specificity of activated lymphocytes is provided. The present method can be used to detect the specificity of activated lymphocytes in recipients or patients after organ transplantation or being infected by pathogenic microorganism or vaccination. The establishment of the present invention can not only timely diagnose... Agent: Knobbe Martens Olson & Bear LLP

20070172447 - Agent for preventing and/or treating tissue disruption-accompanied diseases: The present invention relates to an agent for preventing and/or treating diseases accompanied by tissue disruption, which comprises a polypeptide having granulocyte colony-stimulating factor activity as an active ingredient, and a medicament for mobilizing a multipotent stem cell from a tissue into peripheral blood, which comprises a polypeptide having granulocyte... Agent: Fitzpatrick Cella Harper & Scinto

20070172450 - Modulation of immune response and methods based thereon: The present invention relates to methods for the prevention and/or treatment of cardiovascular and allergic diseases and disorders, methods for inhibiting the growth of, or reducing the volume of, a solid tumor, as well as methods for preventing progression to AIDS in an HIV-infected human, by administering a peptide derived... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070172446 - Synthetic chemokine receptor ligands and methods of use thereof: e

20070172449 - Tnf-alpha variant formulations for the treatment of tnf-alpha related disorders: Combination therapies comprising novel TNF-α proteins for the treatment of TNF-α related disorders are provided herein.... Agent: Morgan, Lewis & Bockius, LLP

20070172455 - Chimeric interleukin-6 soluble receptor/ligand protein, analogs thereof and uses thereof: Chimeric proteins constructed from the fusion of the naturally occurring form of the soluble IL-6 receptor and IL-6 which are useful for treatment of cancer and liver disorders, enhancement of bone marrow transplantation, and treatment of other IL-6 related conditions are provided.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172456 - Il-1 zeta, il-1 zeta splice variants and xrec2 dnas and polypeptides: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.... Agent: Immunex Corporation Law Department

20070172458 - Il-6/il-6r fusion protein: The present invention relates to a fusion protein comprising a functional IL-6 molecule and a functional DS-sIL-6R molecule. The present invention also relates to a nucleic acid encoding the fusion protein, methods for producing the fusion protein and the use of the fusion protein in the treatment of infectious diseases... Agent: Banner & Witcoff, Ltd.

20070172457 - Interleukins-21 and 22: The present invention relates to novel human proteins designated Interleukin-21 (IL-21) and Interleukin-22 (IL-22), and isolated polynucleotides encoding these proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing these human proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, and/or preventing... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070172451 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070172452 - Methods for treating viral infection using il-28 and il-29: IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof... Agent: Zymogenetics, Inc. Intellectual Property Department

20070172453 - Tolerogenic approach for type 1 diabetes: The present invention provides compositions and methods for the treatment and prevention of type I diabetes.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070172454 - Use of il-6/il-6 chimera in huntington's disease: The invention relates to the use of an IL-6R/IL-6 chimera, a mutein, isoform, fused protein, functional derivative, active fraction or circularly permutated derivative or a salt thereof, for the manufacture of a medicament for the treatment and/or prevention of Huntington's disease.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172459 - Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules: Compositions of modified cytokines and uses thereof generated using processes and systems for the high throughput directed evolution of peptides and proteins, particularly cytokines that act in complex biological settings, are provided. Also provided are modified cytokines formulated for oral delivery and uses thereof to treat diseases and conditions mediated... Agent: Fish & Richardson, PC

20070172461 - Polyepitope vaccines: The present invention relates to a recombinant polyepitope cytotoxic T lymphocyte vaccine. The vaccine comprises at least one recombinant protein including a plurality of cytotoxic T lymphocyte epitopes from one or more pathogens, wherein the at least one recombinant protein is substantially free of sequences naturally found to flank the... Agent: Steven L. Highlander, Esq. Fulbright & Jaworski L.L.P.

20070172460 - Random peptide library displayed on aav vectors: Described is a method of producing a repertoire of random peptides on the surface of AAV particles wherein said random peptides are expressed as a fusion with an AAV capsid protein of an AAV particle which displays at its surface said random polypeptides. Also described is a peptide library obtainable... Agent: Howrey LLP

20070172462 - Sirna-mediated gene silencing of synuclein: The present invention is directed to small interfering RNAs that down regulate expression of a synuclein gene and methods of using the small interfering RNAs.... Agent: Brinks Hofer Gilson & Lione

20070172466 - Method of replenishing cells damaged by treatment for cancer: A method of replenishing cells damaged by treatment for cancer comprising removing a sample of peripheral blood containing CD34+ pluripotent adult stem cells from a primate mammal, controllably expanding the cells without differentiation at a rate which produces an expansion factor of at least seven times within seven days while... Agent: Ladas & Parry LLP

20070172467 - Regeneration of endogenous myocardial tissue by induction of neovascularization: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject an amount of an agent effective to cause cardiomyocyte proliferation within the subject's heart so as to thereby treat the disorder. This invention further provides the instant... Agent: Cooper & Dunham LLP

20070172463 - Chromobacterium subtsugae sp.nov.and use for control of insect pests: Chromobacterium subtsugae sp. nov., a new species of the genus Chromobacterium which possesses insecticidal activity, is described. The invention also relates to insecticidally-active metabolites obtained from the strain and to insecticidal compositions comprising cultures of the strain and/or supernatants, filtrates, and extracts obtained from the strain, and use thereof to... Agent: Usda-ars-office Of Technology Transfer Patent Advisors Office

20070172464 - Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same: The present invention relates to stem cells which exhibit increased sensitivity to a chemoattractant and, more particularly, to methods of generating and using them such as in clinical applications involving stem cell transplantation.... Agent: Marshall, Gerstein & Borun LLP

20070172465 - Use of umbilical cord blood stem cells to treat ischemic event: The invention relates generally to methods for isolation and culture of umbilical cord blood stem cells, cells isolated by the methods, and therapeutic uses for those cells.... Agent: Viksnins Harris & Padys Pllp

20070172468 - Dietary supplements for reducing cholesterol levels: The disclosure is generally directed to methods and compositions for reducing blood cholesterol levels, and more particularly to dietary supplements for reducing blood cholesterol levels. The dietary supplements for reducing cholesterol typically comprise at least one phytosterol source, at least one soluble fiber source, at least one guggulsterone source, and... Agent: Marshall, Gerstein & Borun LLP

20070172469 - Methods for inhibiting viral replication in vivo: The present invention is directed to methods of modulating viral replication in vivo comprising administering to an individual a therapeutically or prophylactically effective amount of a composition comprising arginine deiminase modified with polyethylene glycol, to methods of concurrently modulating viral replication and treating cancer, and to methods of modulating nitric... Agent: Woodcock Washburn LLP

20070172470 - Phosphatase regulation of nucleic acid transcription: Nucleic acids, polypeptides and methods are provided for regulating the phosphorylation state of the C-terminal domain (CTD) of RNA polymerase II (RNAP II). Also provided are methods for regulating cell differentiation.... Agent: Buchanan, Ingersoll & Rooney LLP

20070172471 - Method for identifying an anti- streptococcal agent and its use for treating streptococcal infections: A method for identifying an anti-streptococcal agent, comprises: (a) providing, as a first component, an isolated streptococcal M protein or a functional variant thereof; (b) providing, as a second component, isolated fibrinogen or a functional variant thereof; (b) providing, as a third component, an isolated β2 integrin or a functional... Agent: Foley And Lardner LLP Suite 500

20070172472 - Methods and systems for treating injured cardiac tissue: Methods and systems are disclosed for treating cardiac tissue by delivering a platelet composition which induces neovascularization in the cardiac tissue. The platelet composition can additionally contain structural materials and/or bioactive agents.... Agent: Medtronic Vascular, Inc.IPLegal Department

20070172473 - Corrosion inhibiting mildew remover kit: The corrosion inhibiting mildew remover kit includes a premeasured amount of sodium perborate, a premeasured amount of a liquid inhibitor and a premeasured amount of a liquid blend. The premeasured amount of sodium perborate, the premeasured amount of liquid inhibitor, the premeasured amount of liquid blend and water combine to... Agent: Naval Air Warfare Center Aircraft Division Office Of Counsel Bldg 435

20070172474 - Dairy components effective for fat loss: The present invention relates to methods comprising administering to an individual regulating body weight calcium-containing whey products in an amount effective to maintain muscle mass, induce weight and/or fat loss, prevent weight and/or fat gain, and/or increase the metabolic consumption of adipose tissue in the individuals.... Agent: Venable LLP

20070172475 - Highly concentrated, liquid formulations of anti-egfr antibodies: The invention relates to processes for the preparation of highly concentrated, liquid formulations comprising at least one anti-EGFR antibody and/or one of its variants and/or fragments, in particular monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), by ultrafiltration. The invention furthermore... Agent: Millen, White, Zelano & Branigan, P.C.

20070172476 - Method of treating b-cell neoplasms or hodgkin's lymphoma: The present invention relates to a method for injuring or depleting a B-cell neoplasm cell or a Hodgkin's lymphoma cell and a method for treating B-cell neoplasm or Hodgkin's lymphoma, wherein each method comprises administering to a patient a monoclonal antibody which specifically binds to a human CC chemokine receptor... Agent: Fitzpatrick Cella Harper & Scinto

20070172478 - Methods of treating skin disorders: Methods of treating skin disorders are provided.... Agent: Leydig Voit & Mayer, Ltd

20070172477 - Use of soluble cd14 for treatment of diseases: Use of soluble CD14 (sCD14) for the manufacture of a medicament for therapeutic or preventive treatment of a disease involving a chronic inflammation condition and a clinical disorder associated with insulin resistance in an animal or a human. Examples of diseases include type 2 diabetes mellitus, obesity, metabolic syndrome, arteriosclerotic... Agent: Hensley Kim & Edgington, LLC

20070172481 - Gdf3 propeptides and related methods: In certain aspects, the present invention provides compositions and methods for regulating body weight, in particular, for treating obesity and obesity-associate disorders. The present invention also provides methods of screening compounds that modulate activity of GDF3. The compositions and methods provided herein are also useful in treating diseases associated with... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070172479 - Protein formulations with reduced viscosity and uses thereof: Protein formulations and methods for reducing the viscosity of a protein formulation are provided. The method for reducing the viscosity of a protein formulation comprises adding a viscosity reducing agent, such as calcium chloride or magnesium chloride to the protein formulation.... Agent: Wilmerhale/wyeth

20070172480 - Recombinant platelet collagen receptor glycoprotein vi and its pharmaceutical use: The invention relates to Glycoprotein VI (GPVI), its isolation, purfication, and methods for recombinant production. Especially, the invention relates to the use of GPVI, preferably recombinant GPVI, in the treatment of disorders and pathological events correlated directly or indirectly to blood coagulation disorders such as thrombotic and cardiovascular diseases, The... Agent: Millen, White, Zelano & Branigan, P.C.

20070172482 - Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins: A method of producing a metalloprotein inhibitor, the method comprising generating antibodies directed at a composition including a metal ion-bound chelator, wherein the composition is selected having structural and electronic properties similar to a functional domain of the metalloprotein, thereby producing the metalloprotein inhibitor.... Agent: Martin Moynihan Prtsi Inc

20070172484 - Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein: The present invention is directed to an immunizing composition containing an antigenic product such as a multiple antigen peptide system (MAPS) or a filamentous bacteriophage displaying an AβPP epitope spanning the β-secretase cleavage site of AβPP and a method for inducing an immune response against the β-secretase cleavage site of... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172483 - Methods for treating conditions associated with masp-2 dependent complement activation: In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070172487 - Alpha-enolase specific antibody and method of use: This invention relates to a method of monitoring cancer development by determining the abundance of alpha-enolase protein wherein increased abundance is an indication of the severity of cancer. In another embodiment, the invention relates to a method of detecting cancer malignancy by determining the abundance of alpha-enolase antibodies in a... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070172488 - Cell growth inhibitors containing anti-glypican 3 antibody: Provided is a cell growth inhibitor that can be used for treating diseases based on abnormal cell proliferation, and in particular cancer. The cell growth inhibitor contains an anti-glypican 3 antibody as an active ingredient.... Agent: Davidson, Davidson & Kappel, LLC

20070172486 - Expression of cyclin g1 in tumors: A method of treating a tumor (in particular osteosarcoma or Ewing's sarcoma) in a host by administering to a host or to the tumor cells an agent which inhibits cyclin G1 protein in an amount effective to inhibit cyclin G1 protein in tumor cells of the host. The agent may... Agent: Wilson Sonsini Goodrich & Rosati

20070172485 - Glycopeptides derived from pancreatic structures, antibodies and applications thereof in diagnostics and therapeutics: The invention relates to a glycopeptide comprising between 1 and 40 repeated C-terminal polypeptides, with 11 amino acids, of BSDL or FAPP, whereby the aforementioned polypeptides are glycosylated and bear glycosylated epitopes giving rise to a specific immunological reaction with induced antibodies in a patient suffering from type 1 diabetes,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070172489 - Caspase inhibitors, especially caspase 3 inhibitors, for the treatment of influenza: The invention relates to the use of at least one caspase inhibitor, in particular a caspase-3 inhibitor, for preparing a pharmaceutical composition for the prophylaxis and/or therapy of a viral infection, in particular an infection with an RNA negative-strand virus, preferably an influenza infection, and to a test system for... Agent: Mayer & Williams PC

20070172490 - Leukocyte stimulation matrix: The present invention relates to a leukocyte stimulation matrix for the simulation of leukocytes and/or the induction of an immunological tolerance comprising a) at least one carrier, b) a soluble matrix for embedding at least one component for generating a leukocyte stimulation and/or the induction of an immunological tolerance, and... Agent: Mh2 Technology Law Group

20070172491 - Vaccine composition comprising an immunoadjuvant compound consisting of a rho gtpase family activator: This invention is based on the experimental finding that activators of Rho GTPases, namely the cytotoxic necrotizing factor 1 (CNF1), and DNT bear immunostimulatory properties towards the systemic response to orally administered ovalbumine. This invention concerns a vaccine composition including an immunoadjuvant compound, wherein the immunoadjuvant compound consists of a... Agent: Young & Thompson

20070172492 - Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant: For the purpose of providing a method of safely and inexpensively producing a fermented plant extract containing an immunopotentiator at a high concentration, the method for fermentation and culture of the present invention ferments a plant component such as wheat flour using Pantoea agglomerans which is a gram negative bacterium... Agent: Armstrong, Kratz, Quintos, Hanson & Brooks, LLP

20070172493 - 12832, a novel human kinase-like molecule and uses thereof: Novel human kinase-like polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length kinase-like proteins, the invention further provides isolated kinase-like fusion proteins, antigenic peptides, and anti-kinase-like antibodies. The invention also provides kinase-like nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention,... Agent: Millennium Pharmaceuticals, Inc.

20070172494 - Cold-adapted equine influenza viruses: The present invention provides experimentally-generated cold-adapted equine influenza viruses, and reassortant influenza A viruses comprising at least one genome segment of such an equine influenza virus, wherein the equine influenza virus genome segment confers at least one identifying phenotype of the cold-adapted equine influenza virus, such as cold-adaptation, temperature sensitivity,... Agent: Heska Corporation Intellectual Property Dept.

20070172495 - Lactobacillus acidophilus nucleic acid sequences encoding cell surface protein homologues and uses therefore: Cell wall, cell surface and secreted protein nucleic acid molecules and polypeptides and fragments and variants thereof are disclosed in the current invention. In addition, cell wall, cell surface and secreted fusion proteins, antigenic peptides, and anti-cell wall, cell surface and secreted antibodies are encompassed. The invention also provides recombinant... Agent: Alston & Bird LLP

20070172497 - Bont/a peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy: The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.... Agent: Mcdermott, Will & Emery

20070172496 - Conjugates of amyloid proteins as vaccines for amyloid-related diseases: New conjugates comprising fragments of amyloid proteins, which may be used in vaccines for the treatment, prevention and/or amelioration of diseases associated with deposition of amyloid proteins, such as, e.g. Alzheimers disease. Methods for treating, preventing and/or ameliorating amyloid-related diseases, by administering a conjugate comprising fragments of an amyloid protein... Agent: Thorpe North & Western, LLP.

20070172499 - Immunotherapy for humans: An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided. A pharmaceutical composition which comprises a bacterial component as an effective ingredient is disclosed, which is used for immunotherapy in a patient suffering from a cancer or microbial infection, wherein the immunotherapy comprises eradicating... Agent: Birch Stewart Kolasch & Birch

20070172498 - Polypeptides for inducing a protective immune response against staphyloococcus aureus: The present invention features polypeptides comprising an amino acid sequence structurally related to SEQ ID NO: 1 and uses of such polypeptides. SEQ ID NO: 1 is a truncated derivative of a full length S. aureus polypeptide. The full-length polypeptide is referred to herein as full length “ORF0594”. A His-tagged... Agent: Merck And Co., Inc

20070172500 - Anthrax antitoxins: The present invention provides compositions useful in preparing and/or serving as antitoxins against Bacillus anthracis, the causative agent of anthrax. The present invention also provides polypeptides and polynucleotides relating to the capillary morphogenisis gene 2 (CMG-2), vectors containing the polynucleotides and polypeptides, and host cells containing related polynucleotide molecules, all... Agent: Fulbright & Jaworski L.L.P.

20070172501 - Method of immunizing humans against salmonella typhi using a vi-repa conjugate vaccine: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce... Agent: Klarquist Sparkman, LLP

20070172502 - Compositions and methods for treatment of toxoplasma gondii and other apicomplexans: Pyrimidine auxotroph mutants of apicomplexans are provided which are mutated in one of six enzymes of the de novo pyrimidine biosynthesis pathway. Also provided are methods of protecting an animal against infection by apicomplexans by administering a pyrimidine auxotroph mutant and methods for screening for inhibitors of pyrimidine salvage enzymes... Agent: Licata & Tyrrell P.C.

20070172503 - Compositions and methods to elicit immune responses against pathogenic organisms using yeast based vaccines: Embodiments of the present invention illustrate methods of treating and preventing infection due to a pathogen such as a fungal pathogen. In particular, the present invention relates to compositions and methods for vaccinations against or treatment for a fungal organism in a non-immunocompromised or immunocompromised subject.... Agent: Faegre & Benson LLP Patent Docketing

20070172504 - In vivo cell surface engineering: The present invention provides methods and compositions for the in vivo engineering of cell surfaces, such as tumor cell surfaces, with one or more immune co-stimulatory polypeptides. The methods, compositions and engineered cells are useful, for example, to stimulate an immune response against the cells. When the engineered cell surfaces... Agent: Foley And Lardner LLP Suite 500

20070172505 - Cosmetic composition comprising at least one specific block copolymer: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium: at least one aqueous phase, at least one preservative, and at least one block copolymer of rod-coil type comprising at least one coil polymeric block structure with a variable conformation covalently bonded to at least one... Agent: Oliff & Berridge, PLC

20070172506 - Osteochondral implant procedure: A surgical procedure for preparing a damaged area of a human knee to receive at least one graft, according to which a moldable material is positioned over the damaged area and removed after it hardens. The mold is used as a template to determine the number and/or a dimension of... Agent: Haynes And Boone, LLP

20070172508 - Transluminal drug delivery methods and devices: Transluminal drug delivery method and device embodiments can include a urethral suppository formulated to prevent or treat diseases of the urethra and surrounding organs, such as interstitial cystitis or urethritis, by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense... Agent: Catalyst Law Group, Apc

20070172507 - Transluminal drug delivery methods and devices: Transluminal drug delivery method and device embodiments may include a urethral suppository formulated to treat diseases of the urethra and surrounding organs by enhancing the absorption of a therapeutic agent of the suppository into body tissues without adversely affecting the natural defense mechanisms of these tissues. Adverse affects on the... Agent: Catalyst Law Group, Apc

20070172509 - Drug delivery system for retarding release of water soluble drugs: An implantable drug delivery system uses a hydrophobic compound as an outer layer or barrier for retarding release of water soluble drugs from the implantable system. The system includes an inner portion of a water soluble drug in a drug matrix material which stabilizes the drug. An outer portion of... Agent: Cindy A. Lynch Conor Medsystems, Inc.

20070172511 - Food products comprising a slowly digestible or digestion resistant carbohydrate composition: A food product comprises an oligosaccharide composition that is digestion resistant or slowly digestible. The oligosaccharide composition can be produced by a process that comprises producing an aqueous composition that comprises at least one oligosaccharide and at least one monosaccharide by saccharification of starch, membrane filtering the aqueous composition to... Agent: Williams, Morgan & Amerson

20070172513 - Encapsulation of oxygen sensitive agents: The present invention relates to the use of a mixture of modified starch and protein for encapsulating oxygen sensitive agents, wherein the modified starch is a starch derivative containing a hydrophobic group or both a hydrophobic and a hydrophilic group which has been further enzymatically hydrolyzed by an exo-enzyme. The... Agent: National Starch And Chemical Company

20070172510 - Energy drink: Disclosed are nutritional energy drinks and supplements. Also disclosed are methods of making nutritional drinks. The drinks provide energy to the body by refueling the body's fuel tank. The drinks comprise a core formula, to which additional ingredients are added to make a energy, performance or diet enhancing formula. The... Agent: Squire Sanders & Dempsey LLP

20070172512 - Methods of preventing peritonitis by administering lactic acid bacterium: The present invention relates to the use of lactic acid bacteria capable of adhering to the mucosa of the intestine and especially colonizing it for the prevention of peritonitis. In particular, the present invention relates to the use of such lactic acid bacteria for the prevention of peritonitis caused by... Agent: Bell, Boyd & Lloyd LLP

20070172514 - Materials and methods for improving livestock productivity: The subject invention provides methods for improving livestock health. In specific embodiments, the invention provides methods for accelerating and/or augmenting livestock growth; improving immunity; and enhancing fertility in livestock. To do so, the present invention provides materials and methods for administering a cysteamine compound to livestock.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070172515 - Film bandage for mucosal administration of actives: The present invention relates to multi-component delivery systems that adhere to mucosal tissue. In particular, the delivery systems include a first delivery vehicle and a second delivery vehicle, which is in association with the first delivery vehicle. The first delivery vehicle may be one or more mucoadhesive films, which may... Agent: Hoffmann & Baron, LLP

20070172519 - Instant sterile adhering functional patch manufacturing machine: An instant sterile adhering functional patch manufacturing machine is disclosed. This machine can be installed at any location. After a consumer deposits the coins and presses the start button, the process is then initiated at the machine. Using the internal operating mechanisms contained inside the main body, the extract solution,... Agent: Wpat, PC Intellectual Property Attorneys

20070172517 - Compositions capable of facilitation penetration across a biological barrier: This invention relates to novel pharmaceutical compositions capable of facilitating penetration of at least one effector across biological barriers. The invention also relates to methods of treating or preventing diseases by administering these compositions to affected subjects.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070172516 - Increasing of the resorption of substances via skin and mucous membranes: The invention relates to the increasing of the resorption of substances via skin and mucous membranes. The invention also relates to substances having an increased capability of being resorbed by skin and mucous membranes, and to pharmaceutical compositions containing substances of this type.... Agent: Seed Intellectual Property Law Group PLLC

20070172518 - Method of making silicone pressure sensitive adhesives for delivering hydrophilic drugs: A hydrophobic matrix is prepared by forming a semi-solid composition containing a solid powdered hydrophilic drug and/or a solid powdered hydrophilic excipient, and a silicone polyether, and then adding the semi-solid composition to a silicone pressure sensitive adhesive or a solution containing a solvent and a silicone pressure sensitive adhesive,... Agent: Dow Corning Corporation Co1232

20070172520 - Immunotargeting of nonionic surfactant vesicles: An immunoniosmes for targeted delivery of therapeutic agents to specific tissues in a host and methods of synthesis of those niosomes. An antibody molecule having specificity for a target antigen, such as a cell surface marker or other marker differentially expressed on a target cell, is covalently coupled to a... Agent: Smith Hopen, Pa

20070172522 - Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound: comprising the step of: admixing the same with a polyol and/or a fatty acid ester other than glyceride and a composition obtained by the method. In addition a soft gelatin capsule formulation of the compound of formula (I) obtained by incorporating the compound in a soft gelatin capsule shell comprising... Agent: Sughrue Mion, PLLC

20070172521 - Levetiracetam formulations and methods for their manufacture: Substantially glidant free levetiracetam compositions, pharmaceutical compositions incorporating substantially glidant free levetiracetam compositions, and methods of preparing such compositions are provided.... Agent: Kenyon & Kenyon LLP

20070172523 - Soft-gelatin capsule formulation: The present invention discloses a soft gelatin capsule formulation of a 15-keto-prostaglandin compound, which comprises: a soft gelatin capsule shell comprising gelatin and sugar alcohol as a plasticizer, and a mixture comprising a 15-keto-prostaglandin compound and a pharmaceutically acceptable vehicle which is filled in the shell. By encapsulating the 15-keto-prostaglandin... Agent: Sughrue Mion, PLLC

20070172524 - Process for preparing a solid pharmaceutical composition: The invention relates to a process for preparing a solid pharmaceutical composition of perindopril or a salt thereof which avoids a wet granulation step and results in very stable pharmaceutical compositions, like tablets.... Agent: Swanson & Bratschun L.L.C.

20070172525 - Anti-diabetic combinations: This invention a pharmaceutical composition comprising a DPP inhibitor and a slow release biguanide. The invention further discloses a method of administering a combination comprising a DPP inhibitor and a slow release biguanide to a mammal in need of thereof.... Agent: Ramesh Sesha

20070172526 - Radiopaque fibers and filtration matrices: Medical devices with radiopaque three dimensional filtration matrices provide for improved visualization of the device within a vessel. In some embodiments, the three dimensional filtration matrix comprises fibers, such as surface capillary fibers. Visualization of the three dimensional filtration matrix provides for an evaluation of the proper deployment of the... Agent: Dardi & Associates, PLLC

20070172527 - Environmentally compatible processes compositions and materials treated thereby: Environmentally friendly processes for killing pathogens in water involves adding to the water an amount sufficient of a hydrogen peroxide solution having a pH of less than 4, to kill pathogens in the water, wherein the hydrogen peroxide solution contains metallic ions of silver and at least one of copper... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070172528 - Compositions containing vitamin e and saw palmetto: Mineral additives for preparing tablet compositions that comprise Vitamin E and optionally saw palmetto. The compositions are preferably formulated with a zinc compound and a selenium compound.... Agent: King & Spalding LLP

20070172529 - Herbal formulation for the treatment of piles: The present invention provides a novel herbal formulation for use in treatment of piles. Formulation(s) comprises of leaves of Moringa oliefera, tender leaves of Pongaemia pinnata, whole plant of Cassia occidentalis and leaves of Albizia lebbeck. The formulation can be used as an emulsion or as a soft gelatin capsule... Agent: Ladas & Parry

20070172530 - Beverage: e

20070172531 - Chinese traditional medicine composition for treatment of avian influenza, method for preparation, and application thereof: A Chinese traditional medicine composition for prevention and treatment of avian influenza is provided. Its activated ingredients are consisted of: herba houttuyniae 21.4 wt. %, Caulis lonicerae japonicae 17.9 wt. %, radix isatidis 14.3 wt. %, male fern rhizome 10.7 wt. %, radix et rhizoma sophorae tonkinensis 7.1 wt. %,... Agent: Ladas & Parry LLP

20070172532 - Complex mixtures exhibiting selective inhibition of cyclooxygenase-2: A novel formulation is provided that serves to specifically inhibit the COX-2 mediated inflammatory response in animals. The formulation comprises an effective amount of component I selected from the group consisting of alpha acids and beta acids and an effective amount of at least one component II selected from the... Agent: Mcdermott Will & Emery LLP

20070166272 - Hair cosmetic compositions and process for producing the same: There are provided a hair cosmetic composition capable of imparting a light moistened feel, a good smoothness and a good manageability to hair after drying which is free from frictional feel upon rinsing and exhibit an effect of mending damaged portions of the hair, and a process for producing the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166274 - 7-dimethylamino-6-demethyl-6-deoxytetracycline skin treatment kit: A method to ameliorate the skin-irritating effects of topical tretinoin treatment by providing the tretinoin-using patient with a skin-care kit which includes (1) topical tretinoin; and (2) a skin cleanser formulated to minimize tretinoin-induced skin irritation, and (3) a skin moisturizer formulated to reduce tretinoin-induced skin irritation; and (4) packaging... Agent: Pharmaceutical Patent Attorneys, LLC

20070166295 - Anti-diarrhea preparations for small domestic animals: A composition and method for treating diarrhea in small domestic animals wherein the composition includes an effective amount of kaolin, pectin, at least one probiotic, and a carrier, and the method includes the step of orally administering an effective dosage of the composition to the domestic animals.... Agent: Mcgarry Bair PC

20070166229 - Cardiovascular safety assay: The present invention provides assays and kits for the screening of test compounds for their capability to induce cardiotoxicity in a subject. Said assays and kits are based on the finding that the interaction of astemizole with the HERG potassium channel can be exploited to predict cardiotoxicity of compounds during... Agent: Philip S. Johnson Johnson & Johnson

20070166227 - Crowned dithiocarbamate metal complexes and methods for their use: Compositions containing crowned dithiocarbamate metal complexes and methods of using these compositions; neutral and cationic radioactive metal-nitrido complexes of crowned dithiocarbamates (DTCs) and methods of using these complexes as radiopharmaceuticals for diagnosis and treatment of cardiovascular disorders, infectious diseases, and cancer; tripodal chelatormetal complexes of crowned DTCs and methods of... Agent: Brinks Hofer Gilson & Lione

20070166228 - Neutral labeling reactants and conjugates derived thereof: This invention concerns novel neutral labeling reactants. The novel reactants are derivatives of diethylenetriaminepentaacetic acid (DTPA) diamides, wherein a suitable group is linked to the molecule allowing introduction of the chelating agent or the neutral chelate to bioactive molecules.... Agent: Buchanan, Ingersoll & Rooney PC

20070166230 - Ion channel: Provided are Kv9.2 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3 or SEQ ID NO: 5, and homologues, variants and derivatives thereof. Nucleic acids capable of encoding Kv9.2 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences shown in SEQ ID No. 1,... Agent: Frommer Lawrence & Haug

20070166232 - Magnetic nanoparticles: Magnetic nanoparticles are applicable in imaging, diagnosis, therapy, and biomaterial separation. The magnetic nanoparticles comprise a core represented as FexMavZy and a shell of an inner-transition element Mb or the compound thereof, wherein Ma is an inner-transition element, Z is an element of the group Vla, x is greater or... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20070166231 - Methods and probes for identifying vulnerable plaque: The present application discloses methods for detecting and localizing injuries in the vascular system of a subject, and in particular provides methods for detecting vulnerable or unstable plaques using oligo-deoxynucleotides (ODNs).... Agent: Beyer Weaver LLP

20070166233 - Abuse resistant transdermal drug delivery: A transdermal drug delivery patch has an excipient matrix containing an agonist for administration across the skin of a user, with the matrix further containing a plurality of spaced apart hollow cilia filled with an antagonist, whereby if an abuser attempts to physically remove the agonist the cilia will break... Agent: Kenneth Watov, Esq. Watov & Kipnes, P..c.

20070166234 - Methods and compositions for deterring abuse of opioid containing dosage forms: This invention relates to an abuse deterrent dosage form of opioid analgesics, wherein an analgesically effective amount of opioid analgesic is combined with a polymer to form a matrix.... Agent: Morgan, Lewis & Bockius LLP

20070166235 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070166236 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070166237 - Method for the treatment of bone disorders: Disclosed are methods for treating bone disorders in mammals. The methods comprise a loading period with a bisphosphonate followed by a maintenance period. The loading dose is two to twenty times per day greater than the corresponding maintenance dose. Also disclosed are compositions and kits for implementing the methods disclosed... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166240 - Bronchodilating beta-agonist compositions and methods: Bronchodilating compositions and methods are provided. The compositions are intended for administration as a nebulized aerosol. In certain embodiments, the compositions contain formoterol, or a derivative thereof. Methods for treatment, prevention, or amelioration of one or more symptoms of bronchoconstrictive disorders using the compositions provided herein are also provided.... Agent: Lucas & Mercanti, LLP

20070166238 - Composition and delivery system: A composition for nasal or buccal application comprising a distribution of multilayer microparticles in an inactive base, at least one ingredient having activity on the mucosa of the nose/throat, being adsorbed within the layers of the microparticles so as to be progressively released over time in use; a method for... Agent: Leydig Voit & Mayer, Ltd

20070166239 - Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvant: The present invention provides a polynucleotide adjuvant composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The present invention also provides an immunogenic composition comprising the polynucleotide adjuvant composition together with other immunogenic compositions such as an antigen (e.g., as in a vaccine).... Agent: Bozicevic, Field & Francis LLP

20070166241 - Salicylic acid acne spray formulations and methods for treating acne with same: A fine mist spray of a salicylic acid solution is provided for treating body acne. The pH of the solution may be adjusted to above about 4.5 to reduce the incidence of nasal irritation and coughing due to incidental inhalation of the spray.... Agent: Morrison & Foerster LLP

20070166242 - Oral care product and method for the reduction of dental caries through inclusion of mannan and galactomannan polysaccharides in dentifrice formulations: An oral care composition for reducing colonization of the oral cavity by plaque and disease-causing microorganisms, includes saccharides containing cis-hydroxy sugar units or a derivative thereof. The oral care composition is a dentifrice, mouthwash, chewing gum or a lozenge. The saccharides include monomeric sugars with the cis-hydroxy stereoisomeric structure, polysaccharides,... Agent: Edwin D. Schindler

20070166243 - Composition for toothbrushing: Provided is a dentifrice composition excellent in plaque and stain removing effect and feeling upon use. The dentifrice composition has the following components (A), (B) and (C): (A) from 0.2 to 3 weight % of powder cellulose; (B) a surfactant; and (C) from 10 to 30 weight % of an... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166244 - Compositions comprising silicone pressure sensitive adhesives for delivering oral care substances: Disclosed are compositions for delivering one or more oral care substances to the oral cavity, comprising: (a) a silicone pressure sensitive adhesive selected from a silicone/resin copolymer with silicon-bonded hydroxyl radicals, a silicone/resin copolymer with endcapped silicon-bonded hydroxyl radicals and mixtures thereof; (b) a plasticizing material; (c) a water-soluble bioadhesive... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166245 - Propellant free foamable toothpaste composition: Propellant free foamable aqueous dentifrice system which is capable of being delivered as a foam to a toothbrush and which is stable on the brush and when placed in the mouth and used for tooth cleaning, continues to generate more foam. The system is liquid and as such can not... Agent: Omri M. Behr

20070166246 - Composition for oral cavity: The present invention provides a composition for the oral cavity that comprises a pine bark extract that is extracted from the bark of a pine. The composition for the oral cavity of the present invention can provide a plurality of effects such as an effect of improving blood flow in... Agent: Amin, Turocy & Calvin, LLP

20070166248 - Aqueous photoprotective compositions comprising hydrophilic metal oxide nanopigments and polyalkylene glycols of low molecular mass: Stable, reduced whitening photoprotective compositions contain: a) at least one aqueous phase, b) at least hydrophilic inorganic nanopigments based on metal oxides, in an amount ranging from 1% to 25% by weight, with respect to the total weight of the composition, and c) at least one polyalkylene glycol having a... Agent: Buchanan, Ingersoll & Rooney PC

20070166247 - Method for improving moisturization and hydrating properties lip products: A structured color cosmetic composition comprising water, a phenyl-substituted silicone, nonionic surfactant, and particulates, and a method for improving moisturization and hydration of lips by applying such a composition.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070166250 - Cosmetic polymer composition and cosmetic: The present invention discloses a cosmetic polymer composition containing a straight-chain block copolymer, where the copolymer having a unit derived from a compound having an ethylenic unsaturated bond, having a number-average molecular weight of 1.0×103 to 1.0×106, and having at least two or more glass transition points or melting points;... Agent: Sughrue Mion, PLLC

20070166249 - Pharmaceutical and cosmetic formulations for treating fingernails: e

20070166251 - Composition and method for treating hyperpigmented skin: An improved cosmetic and dermatological composition and a method for treating hyperpigmented skin is disclosed. The composition demonstrates an enhanced ability to lighten mammalian skin color, and is nontoxic and nonirritating. The composition comprises a hydroxycinnamic acid or a methoxycinnamic acid dissolved in a compound having one or more hydroxy... Agent: Marshall, Gerstein & Borun LLP

20070166252 - Method of treating skin requiring tattoo removal: A treatment regimen for treating skin subject to tattoo removal procedures involves the application of supplemental composition(s) such as preparatory composition(s), protective composition(s), and combinations thereof, and a corrective composition.... Agent: Carter, Deluca, Farrell & Schmidt, LLP

20070166253 - Cosmetic and dermatological formulations with natural pigments: Pigment from plant products can be combined with a cosmetic carrier formulation to create a cosmetic and/or dermatological product for transferring color to the skin of the person. A plant product extract or reformulation, such as a concentrate, flake or powder of the plant, can be combined with a cosmetic... Agent: Blakely Sokoloff Taylor & Zafman

20070166254 - Antiperspirant stick compositions: Disclosed are antiperspirant stick compositions comprising specified amounts of antiperspirant active; carrier oil comprising volatile silicone oil and non-volatile masking oil; structurant comprising fatty alcohol and cosmetically acceptable wax having a melting point of 75 to 95° C., a portion of wax comprises polyethylene in specified amounts. Also disclosed are... Agent: Unilever Intellectual Property Group

20070166255 - Treatment of topical discomforts including acne, sunburn, diaper rash, wound, wrinkles and dandruff/hair loss by natural lignans via fatty acid desaturase inhibition: The present invention discloses compositions and methodology based on certain natural lignans that provide treatment of topical discomforts and ailments including sunburn, radiation burn, thermal burn and blisters, diaper rash, shaving burn, wound, venous cannulation, acne, darkened skin pigmentation, skin wrinkles, dandruff, and hair loss; said treatment having achieved via... Agent: Shyam K. Gupta Bioderm Research

20070166259 - Cosmetic composition comprising a tensioning agent and a particular block ethylenic polymer: The present invention relates to a cosmetic composition adapted for a topical application on the skin, especially an anti-wrinkle composition, comprising, in a medium compatible with the skin: at least one tensioning agent, the said tensioning agent being present in a content ranging from 0.01% to 20% relative to the... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070166260 - Hair conditioning compositions comprising polymeric thickeners and method of conditioning hair: The present invention provides the use of a thickening system to provide stable thickened hair treating composition, preferably hair care composition, that can provide enhanced touch, combability, alignment and volume reduction to the hair, with low or reduced greasy, oily hair feel, while being formulated having a thick viscosity with... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166261 - Hair conditioning compositions comprising polymeric thickeners and methods of conditioning hair: The present invention provides the use of a thickening system to provide stable thickened hair treating composition, preferably hair care composition, that can provide enhanced touch, combability, alignment and volume reduction to the hair, with low or reduced greasy, oily hair feel, while being formulated having a thick viscosity with... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070166262 - Leave-on hair care composition: A leave on hair care composition comprising an oil in water emulsion wherein the oil phase comprises: (i) one or more non-volatile oils, where the dynamic viscosity of any single non-volatile oil or the dynamic viscosity of a blend of non-volatile oils is less than 1000 mPa.s at 25° C.... Agent: Unilever Intellectual Property Group

20070166264 - Method of manufacturing purified products of liquid medium-chain alkyl-modified polydimethysiloxane and cosmetics prepared therefrom: A method of manufacturing a purified product of a liquid medium-chain alkyl-modified polydimethylsiloxane that is free of a specific (unpleasant) odor and is practically odorless, the method comprising the steps of: [A] synthesizing a liquid medium-chain alkyl-modified polydimethylsiloxane by carrying out a hydrosilylation reaction between a hydrosilyl-containing polydimethylsiloxane and an... Agent: Dow Corning Corporation Co1232

20070166263 - Vesicles of high molecular weight silicone polyethers: Vesicle compositions from high molecular weight silicone polyether copolymers, methods for preparing the vesicle compositions, and personal, household, and healthcare formulations containing the vesicle compositions are disclosed.... Agent: Dow Corning Corporation Co1232

20070166271 - Mq and t-propyl siloxane resins compositions: Siloxane resin compositions obtained by mixing a MQ siloxane resin with a propyl silsesquioxane resin are disclosed. These siloxane resins are useful in a variety of personal, household, automotive and medical care applications, and in particular, as a resin additive in pigmented cosmetic formulations.... Agent: Dow Corning Corporation Co1232

20070166265 - Cosmetic microemulsion: The present invention relates to a cosmetic microemulsion comprising a non-ionic surfactant type emulsifying agent, a co-emulsifying agent and a solvent selected from the group consisting of hexadecane and isomers thereof and dodecane and isomers thereof, said cosmetic microemulsions having particle diameter smaller than 100 nm. Preferably, this cosmetic microemulsion... Agent: Alston & Bird LLP

20070166266 - Methods and compositions for improving the health and appearance of skin: Provided herein are skin care compositions and methods of improving the health and appearance of skin. Also provided are methods of using polysaccharides for applications such as topical personal care products, cosmetics, and wrinkle reduction compositions. The invention also provides novel polysaccharide molecules useful for improving the health and appearance... Agent: Solazyme, Inc.

20070166267 - Anti-wrinkle composition: A composition is disclosed for treating the skin comprising an acylated short chain bioactive peptide and Lycium barbarum extract product. Also disclosed is a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The composition may contain dimethylisosorbide or... Agent: K.f. Ross P.C.

20070166268 - Thickener compositions comprising sclerotium gum and a copolymer: This invention relates to chemical compositions comprising two thickening components, which are sclerotium gum and a copolymer selected from the group consisting of methyl vinyl ether/maleic anhydride copolymer and acryloyldimethyltaurate vinylpyrrolidone copolymer, in particular the ammonium salt of the latter; which components provide good thickening properties in the presence of... Agent: Philip S. Johnson Johnson & Johnson

20070166269 - Cosmetic composition containing a statistical polymer with a linear chain of ethylenic nature: The present invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one statistical copolymer with a linear main chain of ethylenic nature, in which the said copolymer has a molecular mass of between 15,000 and 600,000 g/mol, contains at least 70% of monomer units derived... Agent: Oliff & Berridge, PLC

20070166256 - Hair cosmetic composition: The present invention relates to a hair cosmetic composition capable of treating hairs without causing damages to hairs and injuries of skins and having oxidation fixing effect of permanent wave and dyeing effect equal to or superior to those in a usual case. Specifically, it relates to a hair cosmetic... Agent: Morgan Lewis & Bockius LLP

20070166270 - Emulsifier concentrate for a cosmetic composition: The invention relates to emulsifier concentrates which are pourable at 20° C. and contain (a) up to 90 percent by weight of a polyethylene glycol fatty acid diester based on a C16-C22 fatty acid, C16-C22 hydroxy fatty acid, polyhydroxy stearic acid, or poly-(C16-C22 hydroxy fatty acid), (b) up to 80... Agent: Cognis Corporation Patent Department

20070166258 - Hair care composition: A hair styling cream comprising: i) an aqueous lamellar phase comprising a) cationic surfactant and b) fatty alcohol having a melting point greater than 35° C. and/or fatty acid having a melting point greater than 40° C.; and ii) 20 wt % or greater of one or more non-volatile liquid... Agent: Unilever Intellectual Property Group

20070166257 - Long wear cosmetic composition: The present invention relates to long-wearing, non-aqueous based cosmetic compositions, and related dermatological, pharmaceutical or hygiene compositions. The present invention provides a non-aqueous based composition comprising one or a mixture of two or more emulsifiers.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070166275 - Compositions comprising kakadu plum extract or acai berry extract: A topical skin care composition comprising kakadu plum extract or acai berry extract, or a combination of both, is disclosed. The composition can include a high oxygen radical absorbance capacity (ORAC) value. The composition can improve the skin's visual appearance, physiological functions, clinical properties, and/or biophysical properties.... Agent: Fulbright & Jaworski L.L.P.

20070166273 - Skin treatment educational kit: A method to ameliorate the skin-irritating effects of topical tretinoin treatment by providing the tretinoin-using patient with a skin-care kit which includes (1) topical tretinoin; and (2) a skin cleanser formulated to minimize tretinoin-induced skin irritation, and (3) a skin moisturizer formulated to reduce tretinoin-induced skin irritation; and (4) packaging... Agent: Pharmaceutical Patent Attorneys, LLC

20070166277 - Polymeric reagents comprising a ketone or a related functional group: Polymeric reagents comprising a polymer attached, either directly or through one or more atoms, to a ketone or a related functional group such as ketone hydrate, thione, monothiohydrate, dithiohydrate, hemiketal, monothiohemiketal, dithiohemiketal, ketal, or dithioketal are provided. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates.... Agent: Nektar Therapeutics

20070166276 - Releasable polymeric conjugates based on aliphatic biodegradable linkers: Activated polymeric bicine derivatives such as Formula (I), as well as conjugates made therewith are disclosed. Methods of making and using the bicine derivatives are also disclosed.... Agent: Lucas & Mercanti, LLP

20070166280 - Chemokines as adjuvants of immune response: Dendritic cells play a critical role in antigen-specific immune responses. Materials and methods are provided for treating disease states, including cancer, infectious diseases, autoimmune diseases, transplantation, and allergy by facilitating or inhibiting the migration or activation of a specific subset of antigen-presenting dendritic cells known as plasmacytoid dendritic cells (pDC).... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070166281 - Chloroquine coupled antibodies and other proteins with methods for their synthesis: This invention discloses compositions of chloroquine-coupled active agents such as therapeutic antibodies or insulin, including methods for their preparation. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these... Agent: Kenneth M. Kosak

20070166279 - Method for modulating hla class ii tumor cell surface expression with a cytokine mixture: A method for altering the composition of tumor infiltrating mononuclear cells, increasing CD4+/CD8+ ratio, increasing tumor stroma/epithelial ratio and modulating HLA (Human Leukocyte Antigen) class II expression on a tumor cell surface with a serum-free and mitogen-free mixture having specific cytokine ratios from the group of IL-1β, TNF-α, IFN-γ, GM-CSF,... Agent: Roger C. Hahn Hahn & Voight PLLC

20070166278 - Novel g-csf conjugates: The present application relates to novel PEG-G-CSF conjugates in which a PEG molecule is linked to the cyteine residue in position 17 of native G-CSF primary sequence or to the cysteine residue of the corresponding position of a G-CSF analogue. The present application also describes a process for the manufacture... Agent: Mark A Wilson Nektar Therapeutics

20070166282 - Homogeneous preparations of il-28 and il-29: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity... Agent: Zymogenetics, Inc. Intellectual Property Department

20070166283 - Compositions and methods for the treatment of hemophilia a: Improved materials and methods for the treatment of Hemophilia A are provided.... Agent: Dann, Dorfman, Herrell & Skillman

20070166286 - Self-rearranging dna vectors: Disclosed are replicatable viral DNA vectors encoding a site-specific DNA-altering enzyme and a DNA target recognized by the enzyme, the enzyme selectively converting, in a cell expressing the enzyme, the DNA vector to a rearranged form. The invention further relates to methods for assembling recombinant adenoviral DNAs. These methods include... Agent: Clark & Elbing LLP

20070166285 - Systems and methods related to degradation of uremic toxins: The present invention generally relates to the treatment of uremic toxins in vivo using uremic toxin-treating enzymes, and/or cells capable of producing uremic toxin-treating enzymes or otherwise reacting with uremic toxins. Non-limiting examples of cases where the treatment of uremic toxins is desired include renal disease or dysfunction, gout, subjects... Agent: Wolf Greenfield & Sacks, P.C.

20070166284 - Therapeutic regimen for treating cancer: The invention provides a method for treating cancer in a human comprising administering to the human a dose of a pharmaceutical composition comprising (i) a pharmaceutically acceptable carrier and (ii) an adenoviral vector comprising a nucleic acid sequence encoding TNF-α operably linked to a promoter, wherein the dose comprises about... Agent: Leydig Voit & Mayer, Ltd

20070166291 - Cell preparation: A method for transduction of cells with a genetic construct and selection of genetically modified cells, the method comprising performing the transduction and selection in a closed system.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070166293 - Method for growing stem cells: A method for growing stem cells comprising the steps of a providing stem cells with supporters said supporters being genetically modified in order to provide externally regulatable interactions between the supporters and the stem cells; supporters and stem cells are interchangeable upon genetic modification and interaction; applying an external signal... Agent: Jacobson Holman PLLC

20070166292 - System for exsanguinous metabolic support of an organ or tissue: An exsanguinous metabolic support system for maintaining an organ or tissue at a near normal metabolic rate is disclosed. The system employs a warm perfusion solution capable of supporting the metabolism of the organ or tissue thereby preserving its functional integrity. The system also monitors parameters of the circulating perfusion... Agent: Heslin Rothenberg Farley & Mesiti PC

20070166294 - Method for reducing aflatoxins in fodders, meats, milk and derivatives thereof and a composition suitable for said purpose: The invention relates to a method for reducing drastically and/or eliminating aflatoxins in feeds, thus enabling to produce meat and milk free from aflatoxins, by using specific lactic bacteria eliminating the presence of molds from feeds for cattle nutrition and the subsequent aflatoxin contamination of meats, milk and dairy products;... Agent: Pearne & Gordon LLP

20070166287 - Oncolytic virus: The present invention is directed to a method of reducing the viability of a tumor cell involving administering a virus that is not a common human pathogen to the tumor cell. Preferably, the virus exhibits differential susceptibility, in that normal cells are not affected by the virus. This differential susceptibility... Agent: Lewis J. Kreisler

20070166289 - Autologous human dna grafting - anti- & reverse aging process, method: Anti-aging process and method for delivering younger human DNA to tissues, through the periodic infusion (auto-transfusion) of previously harvested autologous younger stem cells, resulting in re-establishment of an earlier relative biological clock set-point, with respect to the number of cell generations-divisions.... Agent: Hogan & Hartson LLP

20070166288 - Formulation to improve survival of transplanted cells: The survival of cells during transplantation is enhanced. Cells to be transplanted are administered in a formulation that provides two ore more survival enhancing factors. Optionally, prior to administration, the cells are cultured in the presence of factors that enhance survival, and may be heat shocked prior to transplantation.... Agent: Bozicevic, Field & Francis LLP

20070166290 - Lineage restricted glial precursors from the central nervous system: A glial precursor cell population from mammalian central nervous system has been isolated. These A2B5+ E-NCAM− glial-restricted precursor (GRP) cells are capable of differentiating into oligodendrocytes, A2B5+ process-bearing astrocytes, and A2B5− fibroblast-like astrocytes, but not into neurons. GRP cells can be maintained by regeneration in culture. GRP cells differ from... Agent: Kathleen A. Tyrrell Licata & Tyrrell P.C.

20070166296 - Therapeutic systems: A compound comprising a target cell-specific portion and human NAD(P)H:quinone reductase 2 (NQO2) or a variant or fragment or fusion or derivative thereof which has substantially the same activity as NQO2 towards a given prodrug, or a polynucleotide encoding said NQO2 or said variant or fragment or fusion or derivative.... Agent: Patrea L. Pabst Pabst Patent Group LLP

20070166297 - Human analogs of murine deubiquitinating protease: The present invention is directed to human analogs of murine hematopoetic-specific, cytokine-inducible deubiquinating proteases (“DUBs”) clustered on chromosomes 4 and 8 and their respective regulatory regions. The nucleotides or proteins encoded thereby my be used in assays to identify inhibitors of human DUBs.... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070166298 - Formulations for the rectal administration of thrombolytically-active agents: Pharmaceutical formulations in suppository form, containing thrombolytic agents, which are able to penetrate rectal mucous, for the treatment of acute hemorrhoid diseases and/or diseases of thrombotic origin.... Agent: Hoffmann & Baron, LLP

20070166299 - Treatment for embolic stroke: Provided herein are methods and compositions for treating stroke that include contacting a subject suffering from a stroke with (1)